# Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study

> **NCT00674362** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 194 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Certolizumab pegol
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00674362
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-05
- **Final completion:** 2010-12
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2012-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00674362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00674362, "Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00674362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*